# EDGAR Filing Document

**Accession Number:** 0001500198
**File Stem:** 0001213900-26-068327
**Filing Date:** 2026-6
**Character Count:** 11610
**Document Hash:** 735bd6440df4786d486b66999d0544cc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-068327.hdr.sgml**: 20260612

**ACCESSION NUMBER**: 0001213900-26-068327

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260612

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260612

**DATE AS OF CHANGE**: 20260612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEUROONE MEDICAL TECHNOLOGIES Corp
- **CENTRAL INDEX KEY:** 0001500198
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 270863354
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40439
- **FILM NUMBER:** 261087523

**BUSINESS ADDRESS:**
- **STREET 1:** 7599 ANAGRAM DR
- **CITY:** EDEN PRAIRIE
- **STATE:** MN
- **ZIP:** 55344
- **BUSINESS PHONE:** (952) 426-1383

**MAIL ADDRESS:**
- **STREET 1:** 7599 ANAGRAM DR
- **CITY:** EDEN PRAIRIE
- **STATE:** MN
- **ZIP:** 55344

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Original Source Entertainment, Inc.
- **DATE OF NAME CHANGE:** 20100830

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported):**, June 12, 2026**

**NeuroOne Medical Technologies Corporation**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40439** | **27-0863354** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

**7599 Anagram Dr., Eden Prairie, MN 55344**

(Address of principal executive offices and zip code)

**952-426-1383**

(Registrant's telephone number including area code)

(Registrant's former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | NMTC | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events.**

On December 21, 2022, NeuroOne Medical Technologies Corporation (the "Company") entered into a Capital on Demand™ Sales Agreement (the "Sales Agreement") with JonesTrading Institutional Services LLC ("JonesTrading") pursuant to which the Company may sell from time to time shares of its common stock, par value $0.001 (the "Shares") through any method permitted that is deemed an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, under which JonesTrading will act as sales agent (the "ATM Program"). On June 12, 2026, the Company filed an updated Prospectus Supplement (the "Prospectus") for the offer and sale of up to $13.4 million of Shares through JonesTrading pursuant to the Sales Agreement.

Honigman LLP, counsel to the Company, has issued an opinion relating to the Shares. A copy of such legal opinion is attached as Exhibit 5.1 hereto.

The Shares will be sold pursuant to the Registration Statement, and offerings of the Shares will be made only by means of the Prospectus. This Current Report on Form 8-K shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdiction

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 5.1 | [Opinion of Honigman LLP](ea029446601ex5-1.htm) |
| 104 | Cover Page Interactive Data File (embedded in Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NEUROONE MEDICAL TECHNOLOGIES CORPORATION** | **NEUROONE MEDICAL TECHNOLOGIES CORPORATION** |
| Dated: June 12, 2026 | By: | /s/ David Rosa |
|  |  | David Rosa |
|  |  | Chief Executive Officer |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](ea029446601_ex5-1img1.jpg) | (313) 465-7000 |

---

June 12, 2026

NeuroOne Medical Technologies Corporation

7599 Anagram Drive

Eden Prairie, MN 55344

---

| | |
|:---|:---|
| ***Re:*** | ***Prospectus Supplement to Registration Statement on Form S-3 (File No. 333-279871)*** |

---

Ladies and Gentlemen:

We have acted as special counsel to NeuroOne Medical Technologies Corporation, a Delaware corporation (the "***Company***"), in connection with (i) preparing and filing with the Securities and Exchange Commission (the "***Commission***") pursuant to the Securities Act of 1933, as amended (the "***Securities Act***"), (a) a Registration Statement on Form S-3 (File No. 333-279871) (as amended or supplemented, the "***Registration Statement***"), declared effective on August 16, 2024, and the prospectus of the Company included in the Registration Statement (the "***Base Prospectus***"), (b) a prospectus supplement to the Base Prospectus, dated as of August 16, 2024, as further supplemented by a prospectus supplement, dated as of April 3, 2025, a prospectus supplement, dated as of August 15, 2025, and a prospectus supplement, dated as of June 12, 2026 (collectively, with the Base Prospectus, the "***Prospectus***"), pertaining to the issuance and sale by the Company from time to time of shares of the Company's common stock, par value $0.001 per share (the "***Common Stock***") with an aggregate public offering price of up to $13,400,000 of shares of the Company's common stock (the "***Shares***") that may be issued and sold under the Capital on Demand™ Sales Agreement, dated as of December 21, 2022 (the "***Sales Agreement***"), by and between the Company and JonesTrading Institutional Services LLC, as the agent.

For the purpose of rendering this opinion, we examined originals or copies of such documents as we deemed relevant. In conducting our examination, we assumed, without investigation, the genuineness of all signatures, the correctness of all certificates, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted as certified or photostatic copies, and the authenticity of the originals of such copies, and the accuracy and completeness of all records made available to us by the Company. In addition, in rendering this opinion, we have assumed that the Shares will be offered in the manner and on the terms identified or referred to in the Registration Statement, the Base Prospectus, the Prospectus, including all supplements and amendments thereto, and the Sales Agreement.

Our opinion is limited solely to matters set forth herein. The law covered by the opinion expressed herein is limited to the Delaware General Corporation Law. We are not rendering any opinion with respect to federal law, including federal securities laws or state blue sky laws.

Based upon our examination of such documents and other matters as we deem relevant, we are of the opinion that as of the date hereof, upon the completion of all Corporate Proceedings (as defined below) relating to the Shares, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, upon issuance, delivery and payment therefor in an amount not less than the par value thereof in accordance with the Corporate Proceedings and the terms of the Sales Agreement, the Shares to be issued and sold by the Company pursuant to the Sales Agreement will be duly authorized by all necessary corporate action of the Company, and such Shares will be validly issued, fully paid and nonassessable.

**Honigman LLP • 650 Trade Centre Way • Suite 200 • Kalamazoo, Michigan 49002-0402**

---

| | |
|:---|:---|
| ![](ea029446601_ex5-1img1.jpg) | (313) 465-7000 |

---

In rendering the foregoing opinion, we have assumed that (i) the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL, (ii) upon the issuance of any of the Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under its Amended and Restated Certificate of Incorporation, as amended (the "***Certificate of Incorporation***") and (iii) certain terms of the Shares to be issued by the Company from time to time will be authorized and approved by the Board of Directors of the Company or one or more committees thereof established by the Board of Directors with the authority to issue and sell Shares pursuant to the Sales Agreement in accordance with the DGCL, the Certificate of Incorporation, the Amended and Restated Bylaws of the Company and certain resolutions of the Board of Directors and one or more committees thereof (with such approvals referred to herein as the "***Corporate Proceedings***") prior to issuance thereof.

We hereby consent to the filing of this opinion letter as <u>Exhibit 5.1</u> to the Company's Current Report on Form 8-K, which is incorporated by reference in the Registration Statement, and to the reference to our firm under the caption "Legal Matters" in the Registration Statement and the Prospectus Supplement. In giving such consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act or the rules and regulations promulgated thereunder by the Commission. This opinion letter is given as of its date based solely on our understanding of facts in existence as of such date, and we disclaim any undertaking to advise you of any subsequent changes in the facts stated or assumed in this opinion letter or of any subsequent changes in applicable law.

---

| |
|:---|
| Very truly yours, |
| /s/ Honigman LLP |

---

**Honigman LLP • 650 Trade Centre Way • Suite 200 • Kalamazoo, Michigan 49002-0402**